Acth for treatment of acute respiratory distress syndrome
AssigneeMallinckrodt ARD IP Limited
InventorsJames KNIGHT, Steve CARTT, David YOUNG, Patrice BECKER
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treatment of acute respiratory distress syndrome comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
Claims23
A method of treating an individual diagnosed with, suspected of having, or preventing in an individual at risk for developing, acute respiratory distress syndrome (ARDS) comprising administration of a therapeutically effective amount of an adrenocorticotropic hormone (ACTH) peptide to an individual in need thereof, wherein the ACTH peptide is one or more of a peptide having a sequence with at least 90% homology to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:
- 9.
A method of increasing the safety of administering an adrenocorticotropic hormone (ACTH) peptide to a critically ill patient comprising a first dosing of about 4 to about 10 days duration wherein the dose is administered as 64 U once per day or 32 U twice a day, followed by one or more subsequent phases of about 4 to about 10 days duration each wherein each successive phase doses is about 50% of the dose of the preceding phase, followed by a final phase wherein the dose of the preceding phase is maintained and administered at intervals of every other day.
Dependencies are inferred from the claim text.